Dianthus Therapeutics (DNTH) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 144.6% versus a loss of 31.3%. Over five years, NAMS leads with a +126.0% price change compared with -21.2% for DNTH. Dianthus Therapeutics is the larger company by market cap ($4.61 billion vs $2.49 billion), about 1.9 times the size, while NewAmsterdam Pharma N.V. is growing revenue faster (-50.6% vs -67.3%).
NewAmsterdam Pharma N.V. converts more of its revenue into profit, with a net margin of -905.7% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | NAMS |
|---|---|---|
| Share price | $82.43 | $21.26 |
| Market cap | $4.61B | $2.49B |
| 1-day change | -2.89% | -3.93% |
| YTD return | +105.97% | -36.92% |
| 1-year return | +144.61% | -31.29% |
| 5-year return | -21.17% | +126.05% |
| EPS (TTM) | $-4.24 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $22.50M |
| Revenue growth (YoY) | -67.35% | -50.61% |
| Net income (latest FY) | $-162.34M | $-203.82M |
| Operating margin | -8739.34% | -1002.90% |
| Net margin | -7973.33% | -905.74% |
| 52-week high | $117.88 | $42.21 |
| 52-week low | $32.22 | $20.94 |
| Distance from 52-week high | -30.07% | -49.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +70.81% | +133.54% |
| Average volume | 821.22K | 1.35M |
| Shares outstanding | 55.93M | 116.90M |
| Employees | 92 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed NAMS by 175.9 percentage points over the past year.
- NewAmsterdam Pharma N.V. is more profitable, keeping -905.7 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- NewAmsterdam Pharma N.V. grew revenue faster in its latest fiscal year (-50.61% vs -67.35%).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
DNTH vs NAMS FAQ
Which is bigger, Dianthus Therapeutics or NewAmsterdam Pharma N.V.?
Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.61B compared with $2.49B for NewAmsterdam Pharma N.V. (NAMS).
Which stock has performed better over the past year, DNTH or NAMS?
DNTH returned +144.61% over the past 12 months, compared with -31.29% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and NewAmsterdam Pharma N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.